ENGLEWOOD, Colo., May 10, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced new clinical findings that further validate and expand the potential utility of its MiOXSYS System as an advanced tool for assessing oxidative stress in human semen, which is broadly implicated as a major cause of male infertility.
Male Infertility
In order to understand the concept of male fertility, a basic understanding of two processes is required. Sperm must undergo a series of steps toward maturation. The next to last step in this series is called capacitation. (Article also has audio)
If you've been going through treatment for a long time - have you ever felt like this?
What do men, directions and infertility have in common?
In any field of medical research, success is often measured in minute degrees, the impact of which may only be known to those whose careers are spent in the laboratories. Occasionally, however, there comes a discovery so astounding that it revolutionizes medical procedure. Such is the case with Intracytoplasmic Sperm Injection, or ICSI, a new infertility treatment utilizing micromanipulation technology that specifically addresses male factor infertility issues. ICSI is so remarkable, in fact, that most treatments previously used have been abandoned in its favor.
Couples and individuals facing reproductive choices have many options available to them today. Just a few decades ago, if a patient needed donor sperm their physician made all the choices for them and had little information to share about the donor.